| Titre |
Étude de phase III: Radiothérapie par modulation d'intensité préopératoire VS post-opératoire pour les sarcomes des tissus mous du tronc et des extrémités. |
| Protocole ID |
RxTx 50/50 |
| ClinicalTrials.gov ID |
n.d. |
| Type(s) de cancer |
Sarcome |
| Phase |
Phase III |
| Type étude |
Traitement |
| Institution |
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
 PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
5415 boul. de l'Assomption, Montréal, QC, H1T2M4
|
| Ville |
Montréal |
| Investigateur(trice) principal(e) |
Dr Nader Khaouam
|
| Coordonnateur(trice) |
Jany Barry
514-252-3400
|
| Statut |
 Actif en recrutement |
| Critètes d'éligibilité |
- Histologically proven soft tissue sarcoma of the extremity or trunk following review by local reference pathologist.
- Deemed appropriate for preoperative or postoperative radiotherapy and conservative surgery following patient assessment by a radiation oncologist and surgical oncologist.
- Lesion is primary or locally recurrent. Patient may have undergone excisional biopsy with positive margins at a referring hospital and are eligible following discussion among the surgical oncologists and radiation oncologists that IMRT is an acceptable treatment for that case.
- ECOG 0-3
- Patient is aged 18 years or older.
- Patient is able to provide informed consent
- Patient is available for treatment and follow-up.
|
| Critètes d'exclusion |
- Benign histology.
- Prior malignancy within the previous five years or concurrent malignancy with the exception of adequately treated basal cell carcinoma of the skin or carcinoma in-situ of the cervix.
- Prior radiotherapy to the target site
- Planned chemotherapy for (neo)adjuvant treatment
- Conservative surgery to the target site only
- Presence of regional nodal disease or unequivocal distant metastases.
- Other major medical illness deemed to preclude safe administration of protocol treatment or required follow-up.
|
Groupe d'étude en oncologie du Québec